HUM Stock Price Today (July 2026) — Humana Inc. Analysis & Key Metrics 2026-07-17
Humana Inc. (HUM) is trading at $400.00, up 3.50% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $304.33 (-23.9% upside).
- Volatility remains elevated (32.67% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (23.50% YoY) alongside significant competitive pressures.
HUM Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Humana Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $40.16B
P/E Ratio
Forward P/E: 25.25
Revenue Growth
Year over Year
Analyst Target
+-23.9% upside potential
Key Investor Questions About HUM
What investors need to know before buying
Based on current market data, HUM presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 58.58)
- Fundamentals say: Caution warranted (high leverage concerns)
HUM's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HUM investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $14.37B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, HUM stock traded between $163.11 and $398.80—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.67% annualized volatility and β=0.39, the stock exhibits low sensitivity to market moves—making HUM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Did Rising Analyst Earnings Estimates and Zacks Rank Upgrade Just Shift Humana's (HUM) Investment Narrative?
Earlier this week, Humana reported that analysts have increasingly raised their earnings estimates, with the stock’s analyst rating improving to a Zacks Rank #1 (Strong Buy) and sentiment strengthening around its near-term outlook. The strong agreement among analysts on higher profit expectations, especially within a Medical HMO industry that has itself risen meaningfully this year, highlights growing confidence in Humana’s business relative to peers. Now we will explore how this stronger...
What A Patient Holder Is Really Paying For CVS Health Stock
The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.
What's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets?
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?
Here is how Humana (HUM) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
UnitedHealth Jumps 10.3% After Raising 2026 EPS Outlook Above Estimates
Stronger medical costs and better-than-expected quarterly profit lifted guidance and boosted confidence in the earnings recovery.
Why UNH Stock Breakout Faltered After Massive Earnings Beat
UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs, sending the Dow Jones stock surging past a buy point on Thursday morning. Rival managed-care providers including Humana, Centene and Elevance Health got a sizable lift from the initial warm reception for UnitedHealth's earnings report. Results: UnitedHealth posted Q2 earnings per share of $6.38, up 56% from a weak year-earlier result and 30% ahead of $4.91 forecasts.
Can Humana (HUM) Run Higher on Rising Earnings Estimates?
Humana (HUM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Inside the UnitedHealth Earnings Beat That Lifted Healthcare Stocks
The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.
UnitedHealth stock jumps on Q2 earnings, raises full-year outlook
Insurance giant UnitedHealth Group (UNH) is out with its second quarter earnings on Thursday, raising its full-year outlook alongside its reported $112 billion in quarterly revenue. The stock has jumped in Thursday trading. Mizuho Americas healthcare equity strategist Jared Holz takes a closer look at the insurer's stock performance and the role Medicare Advantage had in its figures.
The Medicaid Problem That Swallowed an Earnings Beat
Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.
Frequently Asked Questions
Common investor questions about Humana Inc.
Humana Inc. (HUM) is currently trading at $400.00. The RSI (14-day) is at 58.6, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $304.33 implies 23.9% downside from current levels. Volatility is moderate at 32.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Humana Inc. (HUM): The trailing P/E ratio is 42.69, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 25.25, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.25, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 2.58. Price-to-Sales is 0.35. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering HUM, the consensus price target is $304.33. This represents a 23.9% downside from the current price of $400.00. The range spans from a low target of $195.00 to a high target of $441.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Humana Inc. (HUM) pays a dividend with a current yield of approximately 89.00%. The annualized dividend rate is $3.54 per share. The payout ratio is 37.8%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-26T00:00:00.000Z.
Key risks for Humana Inc. (HUM) investors include: 1. Moderate volatility (32.7% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Humana Inc.'s (HUM) current debt and financial health profile: Total debt stands at $14.37B. The debt-to-equity ratio is 77.07, which is moderate and generally manageable for most companies. The current ratio is 1.77, indicating strong short-term liquidity. The quick ratio is 1.26. The company holds $21.97B in cash and equivalents. Free cash flow is positive at $1.43B, providing a cushion for debt servicing and shareholder returns.